The Freedom Portfolio – July 2021

July 10, 2021 paul.essen Comments 2 comments

I struggled a bit with what to write about for my quarterly recap this time around. In many ways, it has felt like the world has been in a bit of a holding pattern over the past few months as it waits to see how things shake out. Will a new COVID variant kick off a second wave which leads to new lockdowns? Will the Federal Reserve continue to keep rates low or will less-than-transient inflation cause them to take action? Will we continue to be seeing supply shortages and what areas might be next? Will surges in remote work and ecommerce during COVID stick around? How quickly will people be going back to cruises and movie theaters and airplanes? How long can Wall Street Bets and retail investors keep the meme stocks going? Are cryptocurrencies the wave of the future or a bubble in the process of bursting? Can the red-hot real estate market continue or are we looking at another housing crash? How will the streaming wars shake out? How does online advertising deal with the privacy changes being enacted by Apple and Google?

In many ways, this was reflected in my behavior during the quarter. I only wrote three posts and fewer changes to my portfolio than is typical. I think a lot of that is because, much like the rest of the world, I’m also waiting to see how things shake out and where certain long term trends go. For many of the questions I posed above, I have companies whose fates are closely entwined with the answers. If COVID lockdowns come back in some form we might see even more growth in ecommerce (SHOP, MELI, SE), and digital payments (SQ), and streaming (ROKU, DIS), and remote work (ZM). Bitcoin recovering from its recent stumble would undoubtedly be bullish for Square. A real estate bubble bursting would spell trouble for Redfin (RDFN). There are a lot of moving parts in the future of advertising which will ultimately determine how companies like The Trade Desk (TTD), Magnite (MGNI), and Roku (ROKU) will end up.

So that seems to be the theme of this past quarter: being in a holding pattern. It seems pretty fitting given my long term focus. There shouldn’t be any rush to make snap judgements on trends that are going to take years to play out.

Speaking of long term trends, here’s the updated Freedom Portfolio performance including the most recent quarter:

As you can see, it’s been a nice rebound from the drop last quarter as the Freedom Portfolio basically doubled the performance of the S&P 500 in Q2 16% vs 8%. The S&P 500 is still well ahead for 2021 as a whole, though, so this might be one of those years where I lose to the market. After the performance I had in 2020, I can’t be too upset with that.

Here are the returns of each of my positions over the past quarter:

Ticker	Quarterly Change
NVCR	66%
CELH	51%
SWAV	44%
FUBO	43%
ROKU	38%
CRWD	34%
SHOP	26%
AXON	24%
ZM	19%
TTD	17%
SE	16%
SKLZ	16%
FVRR	8%
SQ	6%
MELI	3%
TSLA	3%
SNOW	2%
ETSY	-1%
JD	-5%
DIS	-7%
RDFN	-8%
TDOC	-9%
BFLY	-11%
TMDX	-17%
DMTK	-19%
MGNI	-21%
NNOX	-22%

Notable Performers

Best Performers

NovoCure (NVCR): 66% gain: Novocure might have had the most exciting quarter of any other stock in the Freedom Portfolio. Part of it is because it was up a whopping 66% for the quarter, but part of it is also due to the fact that it popped 50% in one day in April due to overwhelmingly good results for its phase 3 trial for using Tumor Treating Fields on non-small cell lung cancer. This is a company which has more than tripled over the past year and sports a market cap over $20 billion, but I think there’s still room for growth. The treatments for which Novocure has FDA approval still tend to be rarer forms of cancer and there are many trials ongoing to study the efficacy of Tumor Treating Fields on more common forms of cancer. Additionally, no other company seems to be developing any similar treatments, so this is a field that Novocure could completely own. I’m happy to continue holding on to my full position despite the big gains.

Celsius (CELH): 51% gain: Celsius is one of those companies well outside my comfort zone. What kind of disruptive innovation can a beverage company provide? What kind of durable moat can it have? Anybody familiar with the story of Monster Beverage (MNST) can certainly provide an answer. For those who don’t know, Monster Beverage (the energy drink company) is one of the best performing stocks of this century, having outperformed such massive successes as Apple (AAPL) and Netflix (NFLX). I’ve done some research (discussions with the younger generation and some first hand beverage consumption) and I think there’s a decent chance that this “healthy” (put in quotes because I’m a bit skeptical of the claim) energy drink could be a decent sized winner going forward.

Shopify (SHOP): 26% gain: Not the biggest percent gain among the Freedom Portfolio, but notable for being such a large jump for my largest holding. Despite having had an exciting journey during that time, Shopify is essentially flat over the past 5 months as people undoubtedly are trying to figure out how much of the ecommerce surge that happened during COVID is here to stay. More than a play on ecommerce, though, I see Shopify as a play on entrepreneurship. For a variety of reasons, I believe people are getting less and less content working a typical 9-5 office job and are looking for something that will give them more freedom. For those who are also interested in being their own boss, I think Shopify has a compelling offering, and I believe that will continue to be a powerful tailwind for the company going forward.

Worst Performers

Nano-X (NNOX), DermTech (DMTK), and TransMedics Group (TMDX): 22%, 19%, and 17% losses: It seemed only fitting to combine these three companies since they represent three out of the four biggest losers during the past quarter and they are in similar situations to each other. All have potentially revolutionary new ways of addressing a medical issue. All of them are early in their life cycle and are either waiting on things like FDA approval or general acceptance from the medical establishment. I expected volatility from all of them so it doesn’t surprise me at all to see them all bringing up the rear in terms of performance this past quarter. If things work out for any of these companies, I fully expect them to be big winners in the coming 5+ years. However, I also think there’s a very good chance things don’t work out, which is why they currently remain small positions for me.

Changes in the Portfolio

Not a ton of changes in the portfolio over the past quarter, but those few changes were pretty seismic as I sold two of the positions that I have held the longest:

Saying goodbye to some old friends